It’s time for a new era of public health—where vaccines are seen as both a scientific triumph and a shared commitment to well ...

GSK Plc’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its ...

Some health professionals have spoken out about President Donald Trump’s nomination of Robert F. Kennedy, Jr., for Secretary ...

GSK Plc’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its return to cancer medicines. While GSK already agreed to multiple deals in ...

Two Senate committees are expected to question Robert F. Kennedy Jr. on how his disproven views of science and medicine ...

Emma Walmsley has also been busy shaking up the company and has replaced 50 top managers, around 40% of the company’s management. Pfizer said in October that it is considering selling its ...

The company said under a collaboration with the university it would invest £50m over three years to find out whether cancers ...

Speculation is mounting GlaxoSmithKline's CEO Emma Walmsley may pay the price for the company’s lacklustre performance, after the dreaded activist investor Elliott Management built a stake in ...

Ana Botin, executive chair of Spanish bank Santander has denied reports that the company is considering leaving the British ...

GSK Plc CEO Emma Walmsley talks about buying US cancer biotech IDRx for as much as $1.15 billion, expanding their portfolio in the US, their overall drug pipeline and working with Robert F.

GSK's purchase of the group further expands its oncology portfolio, which has grown in recent years under chief executive Emma Walmsley amid investor pressure. It acquired TESARO, developer of ...